menu
    • menu
    [{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Research \/ Not Applicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"C5-RIBOTAC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Research \/ Not Applicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"AS01B","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"Scripps Research \/ IAVI"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Scripps Research \/ Scripps Research"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Research \/ Scripps Research"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Amazentis","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Scripps Research","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Research \/ Scripps Research"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Gates MRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CLB073","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Gates MRI","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Research \/ Gates MRI"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scripps Research \/ Scripps Research","highestDevelopmentStatusID":"14","companyTruncated":"Scripps Research \/ Scripps Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Scripps Research

    Menu

    Scripps Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Alloy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alloy And Scripps Partner on ATX-Gx™ Platform for Antibody Discovery

                            Details : The agreement provides Scripps Research scientists with broad access to Alloy’s fully human transgenic mouse platform, which has the power to increase the pace and success rate of antibody discovery.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Alloy Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Calibr-Skaggs Expands License Agreement with AbbVie for Cell Therapies in Solid Tumors

                            Details : Under the agreement, AbbVie will explore Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapies in solid tumor indications and autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 06, 2024

                            Lead Product(s) : CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLB073

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Gates MRI

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Calibr and Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tu...

                            Details : Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment.

                            Brand Name : CLB073

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : CLB073

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Gates MRI

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urolithin A

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Recipient : Amazentis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Study Shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and All...

                            Details : Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from f...

                            Brand Name : Mitopure

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 07, 2022

                            Lead Product(s) : Urolithin A

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Recipient : Amazentis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antiviral Therapeutic

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19

                            Details : The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation to deliver next generation oral antiviral treatments.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 15, 2022

                            Lead Product(s) : Antiviral Therapeutic

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Bridge Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and No...

                            Details : Under the terms of the multi-year collaboration agreement, Scripps will conduct research and development activities, and Bridge Biotherapeutics will retain an exclusive option to acquire worldwide license and patent rights from the research program.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 08, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Bridge Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : eOD-GT8 60mer,AS01B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : IAVI

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First-in-Human Clinical Trial Confirms Novel HIV Vaccine Approach Developed by IAVI and Scripps Research

                            Details : EOD-GT8 60mer showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.

                            Brand Name : eOD-GT8 60mer

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 03, 2021

                            Lead Product(s) : eOD-GT8 60mer,AS01B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : IAVI

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C5-RIBOTAC

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Scientists Discover Small Molecule that Targets, Destroys RNA Sequence of Virus that Causes COVID-19

                            Details : Scientists from Scripps Research have created drug-like compounds that, in human cell studies, bind and destroy the coronavirus’ clutch-like device which helps in viral replication, thus ceasing its spread.

                            Brand Name : C5-RIBOTAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : C5-RIBOTAC

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scripps Research

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS

                            Details : The study, published in Science, is the first to map a human antibody’s interaction with the new coronavirus at near-atomic-scale resolution.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 03, 2020

                            Lead Product(s) : SARS-CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth